


LIVERSTAT

A Clinical Aid for Steatotic Liver Disease* (SLD) and Liver Fibrosis



*formerly called NAFLD (Non-alcoholic Fatty Liver Disease)

LIVERSTAT as your first-line clinical aid for advanced fibrosis and steatosis risk assessment in patients with metabolic syndrome (MetS)




of patients with NAFLD present with normal liver enzymes and are **underdiagnosed**



develop NASH in cases of NAFLD especially in the presence of type 2 diabetes




patients with diabetes present with normal ALT despite **advanced liver fibrosis**



A liver ultrasound is **unable to stage liver fibrosis**

What is LIVERSTAT ?

LIVERSTAT is a blood-based test utilising 7 biomarkers from patient's blood draw and their anthropometrics to generate a quantitative fibrosis assessment and to determine the presence of steatosis only in those subjects without fibrosis.



High risk conditions for SLD and Metabolic Dysfunction-Associated Steatohepatitis* (MASH)

*formerly called NASH (Non-alcoholic Steatohepatitis)



Obesity



Diabetes



Hypertension



Dyslipidemia



OSA*



Bariatric Surgery Indication



PCOS*

7 Blood Biomarkers:

- Triglycerides
- Total Cholesterol
- Fasting Glucose
- Total Bilirubin
- AST
- ALT
- GGT



4 Anthropometrics:

- Age (Date of Birth)
- Weight
- Height
- Gender

- High performance for severe fibrosis detection

AUROC (95% CI) for bridging fibrosis (F3F4)

	Training cohort N=270	Validation cohort N=310
LIVERSTAT	0.806 (0.737 - 0.841)	0.759 (0.701 - 0.808)
FIB-4	0.807 (0.630 - 0.756)	0.757 (0.698 - 0.805)
P value	NS	NS

Compared to FIB-4, **LIVERSTAT** has several advantages:

- Provides grading of steatotic liver disease from simple steatosis to advanced fibrosis
- No grey zone
- Analytically calibrated
- No drawbacks related to age, gender, ethnicity or diabetes



Look for NAFLD in patients with Type 2 Diabetes Mellitus, irrespective of liver enzyme levels, due to high risk of disease progression.

EASL-ILC, 2016

Managing SLD* (NAFLD) risk with LIVERSTAT



- Order **LIVERSTAT** for all MetS patients as first-line clinical aid
- Receive **LIVERSTAT** report for:
 - **Class A** - No presumed liver fibrosis. No presumed steatosis
 - **Class B** - No presumed liver fibrosis. Presumed steatosis
 - **Class C** - Presumed liver fibrosis, mild or moderate
 - **Class D** - Presumed liver fibrosis, advanced (severe)
- Determine the best patient management plan:
 - Intensive lifestyle change
 - MetS correction
 - Referral to liver specialist
 - Monitor progression with **LIVERFAST™***

*LIVERFAST™ is a clinical aid for staging and monitoring of liver damage related to NAFLD, NASH, chronic viral hepatitis B and C and for prognostication of liver related outcomes in NAFLD and NASH.

Simple and Convenient with Immediate Results



Physician prescribes **LIVERSTAT** for the patient



Lab analyses 7 biomarkers from **1 blood sample**



Input patient **biomarker results** and their **specific anthropometrics** into Fibronostics's proprietary Artificial Intelligence (AI) platform



LIVERSTAT results are **available immediately**

Abbreviations

AI Artificial Intelligence
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
GGT Gamma Glutamyl Transpeptidase
MetS Metabolic Syndrome
OSA Obstructive Sleep Apnea

PCOS Polycystic Ovary Syndrome
NAFL Non-alcoholic Fatty liver
NAFLD Non-alcoholic Fatty liver disease
NASH Non-alcoholic Steatohepatitis
MASH Metabolic Dysfunction-associated Steatohepatitis
SLD Steatotic Liver Disease

For more information,
www.fibronostics.com